In an 80,000 m2 site 20 miles from Rome, young researchers from around the world work day and night making history. They have played a key role in the development of the Covid-19 vaccine, after the Jenner Institute (expert in coronavirus) sent them the viral inoculum and asked them for help. IRBM in Pomezia (Rome) has in fact a great experience in adenovirus, the viral vector. «We are producing and shipping the doses: phase III is underway» say Piero Di Lorenzo, President of IRBM, «if everything goes as planned, and it’s a big if, the first doses could be available in Italy between November and December». For IRBM – 43 million turnover reflecting the activity of a centre of excellence – this is an epoch-making challenge.
- previous post: «The anti-covid vaccine in pharmacies in January» Piero Di Lorenzo, President of IRBM in Pomezia (Rome): «It will cost 2-3 euros, two billion doses will be produced in a year. Italy can rest assured»
- next post: Interview with Piero Di Lorenzo “Vaccine, 2 million doses within this year. The vaccine will be safe despite skipping steps”